Skip to main content
War in Gaza:: find out how we're responding
Learn more
7392 Results
 
msf-placeholder
Thailand

In Thailand, patient activism is crucial to expanding treatment

In December 1999, over 300 people with HIV/AIDS demonstrated outside the Public Health Ministry for three days, in support of a request by GPO for a compulsory license to allow it to make generic versions of the ARV didanosine (ddI). It was the first time in Thailand that HIV positive people had braved stigmatisation to stage public demonstrations and it proved to be a watershed event. Project Update - 11 Jul 2004
 
msf-placeholder
China

FDCs: fixing access problems

FDCs simplify treatment by significantly reducing the number of pills that need to be taken daily. As they are often made by generic companies, FDCs are also generally much cheaper than the single pills sold by originator companies. Project Update - 11 Jul 2004
 
msf-placeholder
Malawi

Hidden from view : monitoring ARV treatment failure

The problem is that detecting treatment failure at the proper time depends on sophisticated laboratory equipment often not available or affordable in poor countries like Malawi. Project Update - 11 Jul 2004
 
msf-placeholder
South Africa

Second-line ARV treatment: unaffordable luxury?

Xolani has been on antiretroviral treatment at MSF's clinic in Khayelitsha, South Africa, for three years - but now tests indicate that his treatment is failing. Project Update - 11 Jul 2004
 
msf-placeholder
Tuberculosis

TB in an HIV setting: double trouble

More effective and affordable diagnostic tests able to detect TB in HIV positive patients, including extra-pulmonary cases and among children. These tests need to be easy to use even where there is little infrastructure or training. Project Update - 11 Jul 2004
 
msf-placeholder
Ecuador

What is the cost for health care in Ecuador?

A new Presidential Decree threatens to place the commercial interests of the US and multinational pharmaceutical companies above the access to medicines of the Ecuadorian people Press Release - 2 Jul 2004
 
msf-placeholder
Kala azar

Drugs for Neglected Diseases Initiative (DNDi): matching needs and opportunities

Neglected diseases such as leishmaniasis, trypanosomiasis, Chagas disease and malaria have a devastating impact on the world's poor. Project Update - 2 Jul 2004
 
msf-placeholder
Malaria

Malaria patients enter DNDi clinical trials

To ensure a balanced portfolio of drugs in the pipeline, DNDi mixes quick-fix with long-term projects. In the short term, DNDi is developing "fixed-dose" combinations (two drugs combined into one tablet) for uncomplicated malaria: artesunate/amodiaquine for use in Africa and artesunate/mefloquine for use in Asia and Latin America. Press Release - 2 Jul 2004
 
msf-placeholder
Democratic Republic of Congo

Thousands of refugees from DRC gather on border Burundi

Project Update - 28 Jun 2004
 
msf-placeholder
Sudan

West Darfur: "We are looking at a second catastrophe"

"The situation will deteriorate both in terms of the logistics for food supply, but also in terms of epidemics - the seasonal malarial peak is around the corner, and with no latrines, there could be cholera, dysentery, any type of major epidemics. When you think of the global magnitude of the problem - we are talking about one million displaced people - we are afraid tens of thousands of lives could be lost." - Dr. Jean-Hervé Bradol. Project Update - 25 Jun 2004
Cholera intervention in South Kivu
Médecins Sans Frontières (MSF)

Independent medical humanitarian assistance

We provide medical assistance to people affected by conflict, epidemics, disasters, or exclusion from healthcare. Our teams are made up of tens of thousands of health professionals, logistic and administrative staff - most of them hired locally. Our actions are guided by medical ethics and the principles of independence and impartiality. We are a non-profit, self-governed, member-based organisation.

Learn more